CMV infection treatment in transplant patients
Part of Infections clinical trials.
This trial tests whether adding a specific immunosuppressive drug called everolimus can help treat cytomegalovirus (CMV)—a common viral infection that occurs after organ transplants. If you've had an organ transplant and developed a CMV infection, this study may help your medical team find better ways to manage it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You received a solid organ transplant (kidney, liver, heart, lung, or pancreas) and have a confirmed CMV infection detected by blood test
- You are currently taking tacrolimus and mycophenolic acid (MPA) as part of your anti-rejection medications, with or without steroids
- You have not received more than 3 days of antiviral drugs (like valganciclovir or IV ganciclovir) for your CMV infection before enrolling
- Your transplanted organ is working reasonably well and you are not having acute rejection that needs immediate medication changes
- You do not have a known allergy or intolerance to everolimus or mTOR inhibitors
- You are at least 18 years old and able to provide informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a study drug called artesunate as a possible new treatment for CMV (a common virus) in people who have had a kidney, lung, heart, or liver transplant. It is for patients whose CMV infection requires treatment with standard antivirals like ganciclovir or valganciclovir.
This study uses a blood test (QuantiFERON-CMV) to help decide whether people with a silent (no symptoms) CMV infection after a solid organ transplant need treatment. If you have a low-to-moderate level of CMV in your blood without fever or organ issues, this trial may help your doctor choose the safest approach.
This trial tests two different medication strategies to prevent cytomegalovirus (CMV) infection after a kidney transplant. It compares a plan that uses tacrolimus plus an mTOR inhibitor and only treats if CMV appears, versus a standard plan of tacrolimus plus mycophenolic acid with universal prevention therapy.
This trial tests a combination of two antiviral drugs (letermovir and valganciclovir) to treat CMV infections in kidney transplant recipients. It aims to find a safer, more effective treatment option for people with active CMV after transplant.
This trial tests whether giving CMV immunoglobulin (an antibody medicine) after transplant can help prevent a serious CMV infection in people who receive a kidney or liver from a CMV-positive donor. You might be eligible if you are getting one of these transplants and are at high risk for CMV.
This trial tests a special machine that washes a donated kidney with a drug to remove a common virus called CMV before transplant. It may help prevent the virus from infecting the person who receives the kidney.
Hear when a new CMV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.